( Broadest Most Comprehensive Survey Pro...)Nationwide MRSA Prevalence Study to Demonstrate Full Scope of,'Superbug' Threat Facing U.S. Healthcare Facilities and Patients,Health

WASHINGTON, June 21, 2007 /PRNewswire-USNewswire/ -- The following was released today by APIC:

    WHAT:


    -- First nationwide study of the prevalence of Methicillin-resistant

       Staphylococcus aureus (MRSA), a virulent multi-drug resistant organism,

       in U.S. healthcare facilities.


    -- MRSA prevalence study findings significantly exceed previous estimates

       and will for the first time provide a picture of the threat MRSA poses

       to patients in facilities caring for virtually every type of patient,

       including acute care, cancer, cardiac, pediatric, rehabilitation and

       long-term care.


    -- The study, funded by the Association for Professionals in Infection

       Control and Epidemiology (APIC), collected data from more than 1,200

       healthcare facilities in all 50 states to determine the current

       magnitude of MRSA.


    -- Results and implications from the study on MRSA will be discussed at

       APIC's 34th Annual Conference & International Meeting.


    WHEN/WHERE:


      12:00 p.m. Eastern, 9:00 a.m. Pacific, Tuesday, June 26, 2007

      San Jose, CA     Marriott, Guadalupe Room

      301 South Market Street (Directions,

      http://www.apic.org/scriptcontent/custom/sites/ac2007/index.cfm)

                  or

      Media call-in connection: 800-308-9694, enter 400179

      For study results, please go to: http://www.apic.org/MRSAStudy (link

      will be live at 12:01 am, 6/25/07)


    WHY:


    -- In 1972, MRSA accounted for only two percent of all Staphylococcus

       aureus healthcare-associated infections (HAIs) reported to the Centers

       for Disease Control and Prevention (CDC). Today, MRSA accounts for more

    
'"/>




Page: 1 2 
Related medicine technology :

1. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia
Long-Term Safety Data at AAN Annual Meeting
2. First-of-its-Kind National Report Reveals Estimated High Prevalence
and Heavy Cost of Type 2 Diabetes Complications in America
3. Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin
Rashes Caused by Widely Used Cancer Drugs
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement
of Interim Pixantrone Study Results
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis
7. Reaction to Avandia Warnings Stronger Among Internists Than
Endocrinologists, According to Study by GfK Market Measures
8. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
9. Actemra (tocilizumab) Third Phase III Study Results Show
Significant Improvement in Symptoms of Patients with Rheumatoid
Arthritis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. International ENDORSE Study Shows That the Majority of Hospitalized
Patients Surveyed are at Risk for VTE and Many do not Receive
Recommended VTE prophylaxis